Martin and Harris Laboratories Limited Unlisted Shares | Latest Share Price & Updates
Company Overview
Martin and Harris Laboratories share price forms a pivotal element in the company’s journey. Martin and Harris Laboratories was incorporated in 1993 having its headquarters at Gurgaon, Haryana. Martin and Harris Laboratories is an integral part and wing of the giant “Apeejay Group” one of India’s largest and biggest business multinational conglomerates. It is headed by Mrs. Sushma Paul Berlia being a co-promoter and Presidents of Apeejay Stya & Svran Group. The Martin and Harris Laboratories Limited are a few of the wealthiest pharma giants in the industry. This company has been one of the most progressive companies, as it is also aiming for its expansion internationally and it has been awarded as “Best Innovative in process and formulation development” and “Pharma Excellence Award 2018” respectively.
Martin and Harris Laboratories carries out around 52% of Pharma Business and around 48% of Derivative and Investment business. The company is engaged in manufacturing of various pharmaceutical, medicinal, chemical and botanical products. Instead of its core business, it undertook the management of its funds through investment in different avenues fetching good returns, i.e. mutual funds, equity (both quoted and unquoted).
The units of Martin and Harris Laboratories are located at Roorkee and UNA Himachal Pradesh. Thus, it is constantly taking diligent steps to modernize and expand its manufacturing units to meet the international standards.
However, with the industry being in the consumer’s eye, apart from the investments and the stocks which run in the pharmaceutical industry of Martin and Harris Laboratories, the unlisted shares form a major part of the investment commerce as well.
As the unlisted shares, primarily reside with the company’s officials company members, due to the current instauration now it’s possible to buy the pre-IPO shares or say unlisted shares of such company and then sell them at a much higher, thus making a fruitful trade. Martin and Harris Laboratories Limited is considered amongst multi-million players in the pharmaceutical industry which not just have a deep-rooted business but as well can mean to be very profitable for investors and brokers.
It’s very important to thoroughly evaluate the pharmaceutical company you are planning to invest in, given a lot of the company’s stock valuation and major key factors depend on their clean practice and growth rate. Martin and Harris Laboratories Limited is a famous and one of the most crucial pharmacy companies, their unlisted shares is a big grab. But before that, it’s very crucial to eye the company’s – administration, progress, valuation, and account practice being clean /legal or not.
The company has been well known for its expansion over the years and its concrete business models which are not just promising but are effective in the market segment. The administration of Martin and Harris Laboratories Limited is carried out by a bunch of experts which do not just have proficiency but are also quite skilled and experienced, thus making the company’s administration one of the major assets which the company has.
It is also to be believed that Martin and Harris Laboratories have duly experienced major expansion and extension in their staff volume. Along with this, it has also grown over several years as the healthcare industry and pharma industry where both healthcare industry and pharma industry are given equal importance. Being a pharma company, it comes under strict importance for Martin and Harris Laboratories Limited to take into note various laws and precautions while the ship and sell of goods. However, the company’s account practice has been clean and very up to notch from past years and since its time of establishment.
The benefits of having the unlisted shares of Martin and Harris Ltd. Is that the company deals with a wide variety of services in public welfare. Thus, the business can never be off-market as there are too many roots to earn revenue from.
However, the products and services by Martin and Harris Laboratories Limited can be listed as follows-
- Pharmaceutical products
- Medical drugs
- Allopathic
- Clopidogrel
- Nicorandil
- Losartan potassium
- Metoprolol tartrate
The total income of the company is expected at around a numeric value of INR 289.90 crores and the profit after tax (PAT) can be taken down as INR 72.44 crores respectively. However, the Martin and Harris Laboratories Limited total equity can be estimated to a value of INR 258.43 crores along with the company’s market cap which is INR 323 crores. It can be noted that during the financial year 2018-19 company’s profit after tax grew around a percentage of 67.21% compared to the previous year. Such growth was noticed just in a time period of one year. It is also assumed that the total income of the company has increased in the past 4 years. Along with which the company’s operating profit has been increasing which is again a very promising sign. The operating profit has been increasing at a CAGR of around 37.73% taking into count from the year 2016 to 2019.
Business Model
Martin and Harris Laboratories manufactures drugs and medicines for anti-bacterial medicines, Parkinson disease, vaginal infection, anti-spasmodic drugs, fertilization, progestin, vitamin medicines, anabolic steroids, hormonal medicines, ovulatory stimulant.
Martin and Harris Laboratories has 2 manufacturing plants located at Roorkee and Una, Himachal Pradesh.
Martin and Harris Laboratories has one wholly owned subsidiary: Delite Infrastructure Pvt Ltd, engaged in the business of stock investments and financial derivatives (F&O) segment. It consistently distributed dividends for its investors. The company paid dividend of ₹ 2.20 and ₹ 1.80 per share during FY21 and FY20 respectively.
Registered Office
The registered office of the company is located at Village- Pachgaon, NH-8, Delhi-Jaipur Highway, District: Gurgaon, Haryana.
| Symbol | Martin & Harris Laboratories Ltd. |
|---|---|
| Face Value (₹): | 10 |
| ISIN: | INE03VV01015 |
| Demat Status: | NSDL |
| Lot Size: | 15 Shares |
Board of Directors:
| Name | Designation | Profile |
|---|---|---|
| Mr.Harnam Thakur Singh | Director |  |
| Mr.Shanker Laad Laxman | Director | |
| Mr.Ajay Grover | Director | |
| Mr.Gopal Krishna Nigam | Director | |
Conclusion:
Martin and Harris Laboratories Ltd cash flows have been rapidly reduced since the past two years. The same has happened due to a reduction in short term liabilities. The pharma company does have various branches of their own widespread within the country and the Martin and Harris Laboratories Limited are preparing their international exports in the coming years. Thus, the company is going to climb the globe and inflate its domain.
And to the delight of all the investors, the sales and export of all of these are expected to grow at a growth rate of 30 percent and are predicted to reach a value of US $100 billion by 2025. By the way, the Indian pharmaceutical sector is also anticipated to take a higher peak of the graph and show a growth of around Us $100 billion, while the medical device market alone is likely to be subjected to the growth of around US $ 25 billion by the year 2025.
At the same time as export is the key part of any business or trade, the exports including bulk drugs, drug formulations, Biomed, and traditionally made Indian herbs and Ayurveda stand at a value of US$ 20.70 billion, taken in the record as of the year 2020.
Key Business Highlights of The Company & Martin and Harris Laboratories Share Price
- Martin and Harris is among the fastest-growing pharma companies with 29% CAGR sales growth.
- Debt-free company with a D/E ratio of 0.01 (FY2019-20).
- Attractive financials with 21% ROE and 28% ROCE (FY 2019-20) and Martin and Harris Share Price have increased from last year.
- Currently trading at below book value.
Ratio
| Ratio | FY23 | FY22 |
|---|---|---|
| Operating Margin | 40% | 44% |
| Net Profit Margin | 30% | 33% |
| Return on Equity | 11% | 13% |
| Debt-Equity | 0.01 | 0.01 |
| Current Ratio | 26.28 | 33.79 |
| Dividend Payout | 3% | 3% |
Note:- Dividend payout = Total Dividend/Net Income.
It indicates, how much % of its Net Income, the company is paying out as dividend to its Shareholders.
Financial Highlights
| Particulars | 2021-22 | 2020-21 | 2019-20 | 2018-19 | 2017-18 |
|---|---|---|---|---|---|
| Total Income (₹ Crores) | 212.09 | 335.62 | 296.72 | 289.90 | 177.38 |
| PAT (₹ Crores) | 70.16 | 176.86 | 12.73 | 72.44 | 59.37 |
| Diluted EPS (₹) | 175.57 | 442.6 | 31.85 | 181.28 | 148.57 |
| Book Value per Share (₹) | 1,319.62 | 1115.14 | 673.47 | 646.72 | 454.45 |
| Equity (₹ Crores) | 527.33 | 445.61 | 269.12 | 258.42 | 181.60 |
Financial Charts
Shareholding Pattern
Peer Comparison
| Company | Market Cap (₹ Crores) | Profitability Margin (%) | ROCE (%) | ROE (%) | D/E Ratio | P/E Ratio | P/B Ratio | Book Value per Share (₹) |
|---|---|---|---|---|---|---|---|---|
| Martin & Harris Laboratories Ltd | 468 | 30% | 16% | 11% | 0.01 | 6.87 | 0.79 | 1484.69 |
| Themis Medicare Ltd | 1601 | 15% | 20% | 17% | 0.27 | 27.70 | 4.70 | 369.00 |
| Sun Pharmaceutical Industries Ltd | 274400 | 20% | 16% | 17% | 0.12 | 31.10 | 4.92 | 233.00 |
Media Updates
Martin & Harris Laboratories report robust results in FY21, PAT zooms 139 per cent to Rs 177 Cr.
- Martin & Harris Laboratories limited (Manufacturing Arm of Walter Bushnell), has been bestowed with the prestigious “Pharma Excellence Awards-2018 by apex industry chamber ASSOCHAM.
- Martin & Harris Laboratories limited has been presented this prestigious honor for “Best Innovation in Process & Formulation Development. The award was given by Dr. Promila Gupta, Director General of Health Services, Ministry of Health & Family Welfare, Govt of India.
Read more: https://www.facebook.com/WBPharmaceutical/photos/a.201779456838350/625153361167622/?type=3
Frequently Asked Questions
The buying and selling of unlisted shares, and pre-IPO shares is fully legal and valid.
The procedure to buy the Martin & Harris Laboratories shares is fairly simple. Once you have settled on the price and quantity of the transaction, you would have to transfer the funds into the bank account of the seller. Once the funds are transferred and transaction details are shared with the seller, your demat account will be credited with the shares either on the same day of the fund transfer or before the end of the next working day.
In the secondary market, the transactions related to unlisted shares take place with the existing owners of the shares who are generally the employees or existing investors in the company. The company itself is not directly involved.
The Martin & Harris Laboratories shares will get credited either the same day or before the end of the next working day when you transfer the funds into our bank account.
The minimum lot size varies on the basis of market conditions and demand and supply factors. To know the current lot size for Martin and Harris, please visit the stock page on our website: www.delistedstocks.in/current-offerings/martin-and-harris-laboratories-ltd/
There are many factors which influence the pricing of unlisted shares. Apart from the supply and demand factors, the latest transactions happened on the same stock, last funding round of the company, and valuation level of companies of the similar size affect the pricing of the unlisted shares.
Once the selling price and quantity of shares is agreed with us, we will provide you with an UTR (Unique Transaction Reference) number to transfer the shares. Once you have transferred the shares into our company’s demat account, funds are released into your bank account within 24 hours or before the end of the next working day of the transfer of the shares.
If your holding period is less than 2 years, then such income is treated as business income and liable to get taxed as per tax slab of the investor. If your holding period is more than 2 years, then your profits would be subject to long-term capital gains tax. The current short-term capital gain tax rate is 20% after indexation.
The trading in unlisted shares is governed by Securities & Contract (Regulation) Act,1992.which comes under the preview of SEBI. The SEBI regulations become applicable when the stocks of the company get listed on the stock exchange. There is a minimum lock-in period of 6 months for pre-IPO investors.
The major risk associated with investing in unlisted stocks is the liquidity risk. The possible exit route for investors is either to sell to another investor or wait till the company gets listed on the stock exchange.
Yes, NRI’s can also buy and sell Martin & Harris Laboratories shares just like domestic investors. But their investment is on a non-repatriable basis.
The core business of the company is manufacturing pharmaceutical and medicinal chemical products. Besides, the company is also engaged in the business of trading financial derivatives through its 100% owned subsidiary: Delite Infrastructure Pvt Ltd.